NMDA Receptor Antagonist and Use Thereof
US-2024254095-A1 · Aug 1, 2024 · US
Benzimidazole derivatives as PI3 kinase inhibitors
US9872860B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9872860-B2 |
| Application number | US-201514844051-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 3, 2015 |
| Priority date | Oct 6, 2010 |
| Publication date | Jan 23, 2018 |
| Grant date | Jan 23, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a susceptible neoplasm in a mammal in need thereof comprising the steps of: (a) analyzing a sample from said neoplasm to determine whether there is a PTEN deficiency in cells of said neoplasm; (b) selecting a mammal having said neoplasm with PTEN deficiency; and (c) administering a therapeutically effective amount the compound of formula or a pharmaceutically acceptable salt thereof to the mammal selected in step (b).
Assignees
Inventors
Classifications
Drugs for immunological or allergic disorders · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
linked by a carbon chain containing aromatic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9872860B2 cover?
- This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disor…
- Who is the assignee on this patent?
- Glaxosmithkline Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D413/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).